[Click eStock] "Syntekabio, an AI Drug Development Company Expected to Achieve Topline Growth"

NH Investment & Securities evaluated Syntekabio on the 12th as the only domestic company equipped with global AI new drug development capabilities, expecting significant revenue growth centered on AI drug services, joint research and development, and licensing-out (L/O).

Researcher Han Seung-yeon of NH Investment & Securities stated, “Syntekabio has secured compound active substance discovery and lead compound optimization (DeepMatcher) as well as neoantigen prediction (NEO-ARS), and has completed its own data center in Daejeon to secure the necessary computing power.” He added, “The key point to watch for Syntekabio is revenue expansion, aiming to secure additional revenue through promoting cloud service provision to numerous domestic and international pharmaceutical companies, joint research and development, and L/O.”

Researcher Han positively evaluated the company’s core competencies, recognizing the importance of AI drug models, computing power, data, and clinical trials. He explained, “They are striving to build a business model including a cloud-based AI drug development service platform and securing royalty income through partnerships,” and “meaningful growth in the top line is expected.”

Syntekabio is strengthening its AI drug services based on the cloud. In particular, the upcoming SaaS model launch features enhanced usability by providing major AI drug platforms modularly, allowing customers to utilize them according to their needs.

Meanwhile, Syntekabio has secured a new project for responding to emerging infectious diseases, led by the Korea Disease Control and Prevention Agency’s National Institute of Health.

This content was produced with the assistance of AI translation services.